Farmavita.Net member is developing innovative concept for glogal branding and distribution of remedies and devices for therapy of arthritis.
Company is looking to joint-venture, collaborative development or in-licensing of non-prescrition products, on exclusive basis.
For more details please contact Farmavita.Net.
Farmavita.Net member has developed technology which enables development of oral dosage forms with controlled and site specific release of active pharmaceutical ingredients. Patent pending application.
Company is looking for following types of cooperation:
- Joint-venture and private equity partners
- Collaborative product development
- Consulting or contract research contracts
WE REQUIRE PLANT PROVEN COMMERCIAL TECHNOLOGY TO MANAUFACTURE SPECTINOMYCIN HCL IN INDIA . TECHNOLOGY LICENCENSORS/MANUFACTURING COMPANIES/CONSULTANTS TO SUBMIT THEIR TECHNICAL AND COMMERCIAL PROFILE AND BUSINESS TERMS.
CONTACT; MR.ARVIND GANDHI -GM MKTG ( API AND FINE CHEMICALS) ASENCE PHARMA PVT.LTD.,MUMBAI.
The gradual spread of software automation in drug development may be getting a boost from open source systems. Most e-clinical systems today--from data capture and storage to trial management and operations--are proprietary, despite the excellent work that solutions providers have done to make their products compatible with existing standards-based and de facto standard industry systems.
Micro- and nanoscale technologies are emerging as powerful enabling tools for tissue engineering and drug discovery. In tissue engineering, micro- and nanotechnologies can be used to fabricate biomimetic scaffolds with increased complexity and vascularization.
The whole 16 pages article is available for download at Downloads section of Farmavita.Net.
September 9-10, 2014, Parsippany, New Jersey, USA
The Pharma CI Conference & Exhibition is THE INDUSTRY'S GOLD STANDARD for senior level pharmaceutical, biotechnology, medical device, and diagnostics professionals seeking the latest news and the rare chance to network with all the industry's luminaries. This is the biggest and best gathering of pharmaceutical competitive intelligence thought leaders (75+ speakers)!
Seven targeted therapies are available for the treatment of RCC but there is still considerable pipeline activity. Currently approved targeted therapies have been unable to produce durable responses in RCC patients and only delay progression. As a consequence, effective treatment options capable of sustaining responses in RCC are still required.
Invite friends and business partners to join Farmavita.Net
Recommend Farmavita.Net and expand your network!
Go to "Expand Your Network" at Member Menu. There is invitation tool which will help you to import your e-mail addresses from internet or desktop address books. You will be connected to every invited person and also earn two "Good Karma" points for every new member.